MADISON, Wis., June 13, 2011 /PRNewswire/ — Novelos
Therapeutics, Inc. (OTCBB: NVLT), a pharmaceutical company
developing novel drugs for treatment and diagnosis of cancer, today
announced that Harry S. Palmin, President and CEO of Novelos, will
present at the 5th  Lippert/Heilshorn Life Sciences &
Medical Technologies Virtual Conference on Thursday, June 16, 2011,
at 11:30 a.m. Eastern time.

The webcast of the Novelos presentation may be accessed at www.novelos.com

The webcast archive will be available for 90 days following the
presentation.

This day-long virtual conference event includes 30-minute
presentations with accompanying slides from nine industry leaders,
and begins at 9:00 a.m. Eastern time.  The event may be
accessed at the PrecisionIR event site www.vcall.com/CustomEvent/lipper/index.asp

About Novelos Therapeutics, Inc.We are a pharmaceutical
company developing novel drugs for the treatment and diagnosis of
cancer. We currently have three cancer-targeted compounds, which
are selectively taken up and retained in cancer cells (including
cancer stem cells) versus normal cells.  Thus, our therapeutic
compounds directly kill cancer cells while minimizing harm to
normal cells.  This offers the potential for a paradigm shift
in cancer therapy – efficacy versus all three major drivers
of mortality in cancer: primary tumors, metastases and stem
cell-based relapse.  LIGHT is a small-molecule cancer imaging
agent.  We believe LIGHT has first-in-class potential and
expect it to enter Phase 1/2 clinical trials in the third quarter
of this year.  HOT is a small-molecule, broad-spectrum,
cancer-targeted molecular radiotherapeutic that delivers radiation
directly and selectively to cancer cells and cancer stem cells.
 We believe HOT also has first-in-class potential, and we
expe

‘/>”/>

SOURCE